In clinical trials, about two-thirds of people with trauma reported significant, long-lasting relief from PTSD after one or two supervised MDMA sessions.

Transcranial magnetic stimulation (TMS) over the mood-regulating regions of the brain can directly send a signal down the vagus nerve to decelerate the heart rate.

Some patients who achieve rapid remission from depression using an intensive TMS protocol report spontaneously experiencing profound states of mindfulness and being in the present moment.

The psychedelic ibogaine induces a 24-36 hour state often described as "10 years of psychotherapy in a night," where one re-experiences life memories with detached empathy.

Contrary to what might be expected, neuroimaging shows that psychedelics like psilocybin cause an overall decrease in brain activity, not an increase.

Modern researchers argue that psychedelics are too powerful for recreational use and should be treated with more caution than prescription SSRIs, requiring strict medical supervision.

The "Psychiatry 3.0" model views depression not as a permanent chemical imbalance but as a correctable problem in the brain's electrical circuits.

The American Heart Association recently added depression as the fourth major risk factor for coronary artery disease, alongside high blood pressure, high cholesterol, and diabetes.

The Stanford Neuromodulation Therapy (SNT) protocol compresses over six months of traditional TMS therapy into five days by applying stimulation every hour based on spaced learning theory.